Tag Archive | "“drug etfs”"

The Rich ETFs Get Richer, The Poor ETFs Get Poorer

The Rich ETFs Get Richer, The Poor ETFs Get Poorer

The best performing exchange-traded stock funds over the last three months are essentially the same ones that outperformed over the last six months and over one year. The worst performers were consistently weak over all three time periods as well. Simply stated, the rich ETFs are getting richer, while the poor ETFs are becoming impoverished. Consider [...] [...more]

Asia ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Emerging Market ETFs, Health ETFs, Internet ETFs, Latin America ETFs, Materials ETFs, Natural Resources ETFs, Retail ETFs, Special Sectors ETFs, Technology ETFs, US Markets and ETFs Comments (0)

ETFs Worth Considering… Even After the S&P 500’s 7-Week Streak

ETFs Worth Considering… Even After the S&P 500’s 7-Week Streak

As long as interest rates remain low, excess money eventually moves into riskier areas on the spectrum. Higher yielding bonds, convertibles, preferreds, stocks… they all benefit. Of course, if fewer people buy treasuries because they pursue greater risks, the Federal Reserve must continue to offset waning demand. Is $85 billion per month enough? It better be. Consider [...] [...more]

Biotechnology ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Global ETFs, Health ETFs, US Markets and ETFs Comments (0)

Real Estate, Pharma and Dividend ETFs Defy Bearish Predictions

Real Estate, Pharma and Dividend ETFs Defy Bearish Predictions

Citigroup’s Tom Fitzpatrick¬†asserted¬†that the U.S. market is emulating the pattern of a¬†1970s-style bear. The company’s chief technical analyst¬†suggested that stocks would likely fall 20% or more on economic factors like sky-rocketing oil, declining economic activity, rising unemployment and a collapse in housing. There are quite a few¬†problems with Mr. Fitzpatrick’s¬†assertion. Unemployment is woefully high¬†due to a [...] [...more]

Consumer ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Health ETFs, International ETFs, Real Estate ETFs, US Markets and ETFs Comments (0)

5 ETFs For Believers In The Value-Based Pharmaceutical Sector

5 ETFs For Believers In The Value-Based Pharmaceutical Sector

Abbott Laboratories (ABT) sports 5-year dividend growth of nearly 10% as well as a 3.5%+ annualized yield. Eli Lilly (LLY) has a P/E of 9, a 5.3% dividend yield and 3-years earnings growth of 19%. Meanwhile, AstraZeneca PLC (AZN) has a mammoth 35% trailing return on equity with a 5.8% annual dividend payout. How in the world are investors [...] [...more]

Biotechnology ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Strategy, Health ETFs, US Markets and ETFs Comments (0)

ETF Screening Identifies 7 Candidates For Your “Wish List”

ETF Screening Identifies 7 Candidates For Your “Wish List”

Are you wondering if the market can go significantly higher by year end? Maybe your question should take the U.S. market’s remarkable¬†resilience¬†into account. Specifically, the S&P 500¬†has not closed in bear market territory. In fact, the large-cap barometer¬†would have to close below 1096 to get there. Yet,¬†with the exception of¬†a few scary moments, the¬†gauge has¬†demonstrated its [...] [...more]

Biotechnology ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Energy ETFs, Global ETFs, Health ETFs, Large Cap ETFs, Technology ETFs, US Markets and ETFs Comments (0)

5 Surprising Stock ETFs That Are Still “Trending” Higher

5 Surprising Stock ETFs That Are Still “Trending” Higher

The Dow Industrials has dropped below 10,000 for the first time since February 8. Worse yet, the overwhelming majority of stock ETFs are noticeably lower than they were just one month ago. That said, many trend-followers look to the 200-Day moving average to determine the long-term direction of their specific investment. Here are 5 that may or may not surprise [...] [...more]

Biotechnology ETFs, Consumer ETFs, Current Affairs and ETFs, Financial ETFs, Health ETFs, Large Cap ETFs, Mid Cap ETFs, Retail ETFs, Transportation ETFs, US Markets and ETFs Comments (0)

Biotech ETFs Lift Portfolios Higher Than Broad-Based Healthcare ETFs

Biotech ETFs Lift Portfolios Higher Than Broad-Based Healthcare ETFs

Amgen’s got a “Phase 3″ drug in its pipeline called, “Denosumab.” It has possibilities for¬†a range of conditions from¬†osteoporosis to treatment-induced bone loss to¬†rheumatoid arthritis. Genentech has a “Phase 3″ hopeful with “Bevacizumab” (Avastin).¬†This one’s designed to¬†interfere with the blood supply to cancerous tumors. It is believed that¬†if you cut off a tumor’s blood supply, you [...] [...more]

Biotechnology ETFs, Current Affairs and ETFs, ETF Strategy, Health ETFs, US Markets and ETFs Comments (0)

Free Sign-Up                     ETF Expert RSS Feed  Follow EtfExpert on Twitter

Receive ETF Expert Daily By Email
Get The Weekly ETF Expert Newsletter

Archives